Satellos to Participate in November 2024 Investor Conferences
Satellos Bioscience (TSX: MSCL) (OTCQB: MSCLF), a biotech company focused on developing small molecule therapeutics for muscle diseases, has announced its participation in three major investor conferences in November 2024. The company will participate in a fireside chat at the Guggenheim Securities Healthcare Innovation Conference on November 13, deliver a presentation at the Stifel Healthcare Conference on November 18, and conduct one-on-one meetings at the Jefferies London Healthcare Conference from November 19-21. Both the fireside chat and presentation will be available via webcast on the company's website with replay options.
Satellos Bioscience (TSX: MSCL) (OTCQB: MSCLF), un'azienda biotech focalizzata nello sviluppo di terapeutiche a piccole molecole per le malattie muscolari, ha annunciato la sua partecipazione a tre importanti conferenze per investitori nel mese di novembre 2024. L'azienda parteciperà a un fireside chat alla Guggenheim Securities Healthcare Innovation Conference il 13 novembre, terrà una presentazione alla Stifel Healthcare Conference il 18 novembre e condurrà incontri individuali alla Jefferies London Healthcare Conference dal 19 al 21 novembre. Sia il fireside chat che la presentazione saranno disponibili in webcast sul sito dell'azienda con opzioni di replay.
Satellos Bioscience (TSX: MSCL) (OTCQB: MSCLF), una empresa biotecnológica centrada en el desarrollo de terapias de pequeñas moléculas para enfermedades musculares, ha anunciado su participación en tres conferencias importantes para inversores en noviembre de 2024. La empresa participará en un fireside chat en la Conferencia de Innovación en Salud de Guggenheim Securities el 13 de noviembre, realizará una presentación en la Conferencia de Salud de Stifel el 18 de noviembre y llevará a cabo reuniones uno a uno en la Conferencia de Salud de Jefferies en Londres del 19 al 21 de noviembre. Tanto el fireside chat como la presentación estarán disponibles a través de un webcast en el sitio web de la empresa con opciones de repetición.
Satellos Bioscience (TSX: MSCL) (OTCQB: MSCLF)는 근육 질환을 위한 소분자 치료제를 개발하는 데 중점을 둔 생명공학 회사로, 2024년 11월에 열리는 세 개의 주요 투자자 회의에 참여할 것이라고 발표했습니다. 이 회사는 11월 13일 Guggenheim Securities Healthcare Innovation Conference에서 파이어사이드 채팅에 참석하고, 11월 18일 Stifel Healthcare Conference에서 발표를 하며, 11월 19일부터 21일까지 Jefferies London Healthcare Conference에서 일대일 미팅을 진행합니다. 파이어사이드 채팅과 발표는 모두 회사 웹사이트에서 재생 옵션과 함께 웹캐스트로 제공될 예정입니다.
Satellos Bioscience (TSX: MSCL) (OTCQB: MSCLF), une entreprise biotechnologique axée sur le développement de thérapeutiques à petites molécules pour les maladies musculaires, a annoncé sa participation à trois grandes conférences d'investisseurs en novembre 2024. L'entreprise participera à un fireside chat lors de la conférence Guggenheim Securities Healthcare Innovation le 13 novembre, fera une présentation à la Stifel Healthcare Conference le 18 novembre et organisera des réunions individuelles lors de la Jefferies London Healthcare Conference du 19 au 21 novembre. Le fireside chat et la présentation seront tous deux disponibles par webcast sur le site de l'entreprise avec des options de replay.
Satellos Bioscience (TSX: MSCL) (OTCQB: MSCLF), ein Biotech-Unternehmen, das sich auf die Entwicklung von kleinen Molekültherapeutika für Muskelerkrankungen konzentriert, hat seine Teilnahme an drei wichtigen Investorenkonferenzen im November 2024 bekannt gegeben. Das Unternehmen wird am 13. November an einem Fireside Chat auf der Guggenheim Securities Healthcare Innovation Conference teilnehmen, am 18. November eine Präsentation auf der Stifel Healthcare Conference halten und vom 19. bis 21. November Einzelgespräche auf der Jefferies London Healthcare Conference führen. Sowohl der Fireside Chat als auch die Präsentation werden über einen Webcast auf der Unternehmenswebsite mit Replay-Optionen verfügbar sein.
- None.
- None.
Guggenheim Securities Healthcare Innovation Conference
Format: Fireside Chat
Date: Wednesday, November 13, 2024, at 3:30 p.m. ET
Stifel Healthcare Conference 2024
Format: Presentation
Date: Monday, November 18, 2024, at 9:45 a.m. ET
Jefferies London Healthcare Conference 2024
Format: Participation in 1x1 meetings
Dates: November 19 – 21, 2024
The fireside chat and presentation will be available via live webcast on the Events and Presentations page in the Investors section of the Company’s website and a replay will be available following the events.
About Satellos Bioscience Inc.
Satellos is a publicly traded biotechnology company dedicated to developing life-improving medicines to treat degenerative muscle diseases. Satellos has incorporated breakthrough research in muscle stem cell polarity into a proprietary discovery platform, called MyoReGenX™, to identify degenerative muscle diseases where deficits in this process affect muscle regeneration and are amenable to therapeutic intervention. With this platform, Satellos is building a pipeline of novel therapeutics to correct muscle stem cell polarity and promote the body’s innate muscle repair and regeneration process. The Company’s lead program is an oral, small molecule drug candidate in development as a potential disease-modifying treatment for Duchenne muscular dystrophy. Satellos is headquartered in
View source version on businesswire.com: https://www.businesswire.com/news/home/20241104187364/en/
Investors: Liz Williams, CFO, ir@satellos.com
Media: Jessica Yingling, Ph.D., jessica@litldog.com, +1.858.344.8091
Source: Satellos Bioscience Inc.
FAQ
What investor conferences will Satellos Bioscience (MSCLF) attend in November 2024?
When is Satellos Bioscience's (MSCLF) presentation at the Stifel Healthcare Conference 2024?
How can investors watch Satellos Bioscience's (MSCLF) November 2024 conference presentations?
